Literature DB >> 15128761

Cutting edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression.

Karen M Haas1, Franklin R Toapanta, Julie A Oliver, Jonathan C Poe, John H Weis, David R Karp, Joseph F Bower, Ted M Ross, Thomas F Tedder.   

Abstract

Complement component C3 covalently attaches to Ags following activation, where the C3d cleavage fragment can function as a molecular adjuvant to augment humoral immune responses. C3d is proposed to exert its adjuvant-like activities by targeting Ags to the C3d receptor (CD21/35) expressed by B cells and follicular dendritic cells. To directly assess the importance of CD21/35 in mediating the immunostimulatory effects of C3d, CD21/35-deficient (CD21/35(-/-)) mice were immunized with streptavidin (SA), SA-C3dg tetramers, recombinant HIV gp120 (gp120), or gp120 fused with linear multimers of C3d. Remarkably, SA- and gp120-specific Ab responses were significantly augmented in CD21/35(-/-) mice when these Ags were complexed with C3d in comparison to Ag alone. In fact, primary and secondary Ab responses and Ab-forming cell responses of CD21/35(-/-) mice approached those of wild-type mice immunized with SA-C3dg and gp120-C3d. Thus, C3d can function as a molecular adjuvant in the absence of CD21/35 expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15128761     DOI: 10.4049/jimmunol.172.10.5833

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  CR2+ marginal zone B cell production of pathogenic natural antibodies is C3 independent.

Authors:  Keith M Woods; Michael R Pope; Sara M Hoffman; Sherry D Fleming
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

Review 2.  Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity.

Authors:  Franklin R Toapanta; Ted M Ross
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 3.  Molecular structure and expression of anthropic, ovine, and murine forms of complement receptor type 2.

Authors:  Dong Liu; Jian-Ying Zhu; Zhong-Xiang Niu
Journal:  Clin Vaccine Immunol       Date:  2008-04-09

4.  Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.

Authors:  Kelly R Young; Benjamin E Teal; Yvonne Brooks; Thomas D Green; Joseph F Bower; Ted M Ross
Journal:  AIDS Res Hum Retroviruses       Date:  2004-11       Impact factor: 2.205

5.  C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences.

Authors:  Joseph F Bower; Kelly L Sanders; Ted M Ross
Journal:  Curr HIV Res       Date:  2005-04       Impact factor: 1.581

6.  Fusion to chicken C3d enhances the immunogenicity of the M2 protein of avian influenza virus.

Authors:  Zhenhua Zhang; Yongqing Li; Shufang Xu; Fuyong Chen; Li Zhang; Beiyu Jiang; Xiaoling Chen
Journal:  Virol J       Date:  2010-05-09       Impact factor: 4.099

7.  Immunization of DNA vaccine encoding C3d-VP1 fusion enhanced protective immune response against foot-and-mouth disease virus.

Authors:  Huiying Fan; Tiezhu Tong; Huanchun Chen; Aizhen Guo
Journal:  Virus Genes       Date:  2007-05-12       Impact factor: 2.332

8.  Phagocytosis by human neutrophils is stimulated by a unique fungal cell wall component.

Authors:  Ifat Rubin-Bejerano; Claudia Abeijon; Paula Magnelli; Paula Grisafi; Gerald R Fink
Journal:  Cell Host Microbe       Date:  2007-07-12       Impact factor: 21.023

9.  Mannan-binding lectin deficiency modulates the humoral immune response dependent on the genetic environment.

Authors:  Marieta Ruseva; Martin Kolev; Frederik Dagnaes-Hansen; Soren B Hansen; Kazue Takahashi; Alan Ezekowitz; Steffen Thiel; Jens C Jensenius; Mihaela Gadjeva
Journal:  Immunology       Date:  2009-06       Impact factor: 7.397

10.  C3d adjuvant activity is reduced by altering residues involved in the electronegative binding of C3d to CR2.

Authors:  Franklin R Toapanta; Dilhari R DeAlmeida; Matthew D Dunn; Ted M Ross
Journal:  Immunol Lett       Date:  2010-01-12       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.